$EYPT News

EyePoint (EYPT) Stock Sees Fair Value Cut After Duravyu Trial Setbacks

Laidlaw & Co. Downgrades EyePoint to Hold

RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1

Guggenheim Downgrades EyePoint to Neutral

EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts

Most Active Stocks: SAFX, WFF and EYPT in Heavy-Volume Session

EyePoint Drug Trial Flop Crashes Stock. Can a Strategy Shift Save It?

EyePoint: Stock Takes Shellacking On Second Pivotal Eye Disease Study Miss

EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut

EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript

EyePoint Announces 53% Workforce Reduction Following Phase 3 DURAVYU Trial Results

EyePoint Pharmaceuticals to Cut 53% of Workforce After Eye Disease Drug Trial Setback

EyePoint Announces Strategic Prioritization

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO